Clinical Nuclear Medicine

Skip Navigation LinksHome > June 2012 - Volume 37 - Issue 6 > Ipilimumab-Induced Colitis on FDG PET/CT
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318248549a
Interesting Images

Ipilimumab-Induced Colitis on FDG PET/CT

Lyall, Ashima MD; Vargas, Herbert Alberto MD; Carvajal, Richard D. MD; Ulaner, Gary MD, PhD

Collapse Box


Abstract: A 52-year-old woman with metastatic melanoma was treated with ipilimumab. After 2 cycles of treatment, she developed watery diarrhea, sweats, and chills. An FDG PET/CT study demonstrated new FDG-avid (maximum standardized uptake value 15.6) diffuse colonic wall thickening, suggestive of ipilimumab-induced colitis. The patient was treated with systemic steroids, with subsequent resolution of her symptoms. Based on the response to steroids, the diagnosis of ipilimumab-induced enterocolitis was made. Ipilimumab may cause several immune-mediated toxicities, the most common of which is enterocolitis. Physicians interpreting FDG PET/CT examinations of patients treated with ipilimumab should be aware of these FDG-avid immune-mediated toxicities.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.